Cargando…

Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan

Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival outcome. PAH is classified by the 2009 updated clinical classification of pulmonary hypertension and a major subgroup is PAH due to congenital heart disease (CHD) with systemic-to-pulmonary shunt. CHD-PAH is a result o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuuring, Mark J, Vis, Jeroen C, Duffels, Marielle G, Bouma, Berto J, Mulder, Barbara JM
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940744/ https://www.ncbi.nlm.nih.gov/pubmed/20856682

Ejemplares similares

Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease
por: Blok, I.M., et al.
Publicado: (2015)

Recent progress in treatment of pulmonary arterial hypertension due to congenital heart disease
por: Schuuring, M. J., et al.
Publicado: (2011)

The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease
por: van Dissel, Alexandra C., et al.
Publicado: (2017)

Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease
por: van Dissel, Alexandra C., et al.
Publicado: (2018)

Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era
por: Schuuring, M. J., et al.
Publicado: (2011)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study
por: Liao, Shutan, et al.
Publicado: (2018)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009)

Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome
por: van Riel, A. C. M. J., et al.
Publicado: (2016)

Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?
por: Yang, Hayang, et al.
Publicado: (2017)

The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis
por: Kuang, Hong-Yu, et al.
Publicado: (2018)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
por: Wang, Yuchen, et al.
Publicado: (2019)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2009)

Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension
por: Lee, Young Ho, et al.
Publicado: (2013)

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension
por: Amin, Ahmad, et al.
Publicado: (2015)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
por: Pawar, Ravindra, et al.
Publicado: (2009)

The efficacy of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease: A protocol of randomized controlled trial
por: Gao, Chao, et al.
Publicado: (2021)

An implantable loop recorder or smartphone based single-lead electrocardiogram to detect arrhythmia in adults with congenital heart disease?
por: Koole, Maarten A., et al.
Publicado: (2023)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial
por: Vizza, Carmine Dario, et al.
Publicado: (2017)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
por: Jasenovec, Tomas, et al.
Publicado: (2022)

Type D Personality Associated With Increased Risk for Mortality in Adults With Congenital Heart Disease
por: Kauw, Dirkjan, et al.
Publicado: (2022)

Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension
por: Liao, Shutan, et al.
Publicado: (2019)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study
por: Beghetti, Maurice, et al.
Publicado: (2009)

Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers
por: Castellví, Ivan, et al.
Publicado: (2020)

Bosentan monohydrate
por: Kaur, Manpreet, et al.
Publicado: (2012)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3
por: Berger, Rolf M. F., et al.
Publicado: (2017)

Fusion imaging in preoperative planning of mitral valve surgery to prevent injury of the left circumflex artery
por: Man, Jelle Piet, et al.
Publicado: (2022)

Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect
por: Park, Yong Kyu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gqpamfvkh7m42b0lvrpdq538pk